Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates

Autor: Ze Jun Wang, Xing-Lou Yang, Zhiming Yuan, Ya-Nan Zhang, Shuo Shen, Xue Hu, Xin Wan, Zhengli Shi, Yun Peng, Lian Yang, Hua Jun Zhang, Bo Zhang, Jia Wu, Peng Zhou, Kai Zhao, Juan Min, Cheng Peng, Wenhui Wang, Xiao Xiao Gao, Xu Rui Shen, Chao Shan, Ge Gao, Jia Lu, Yan Feng Yao, Ying Chen, Yi Wu Zhou, Li Qian, Jing Guo, Ren Di Jiang, Mei Qin Liu
Rok vydání: 2021
Předmět:
Zdroj: Virologica Sinica
ISSN: 1995-820X
1674-0769
DOI: 10.1007/s12250-021-00376-w
Popis: The ongoing coronavirus disease 2019 (COVID-19) pandemic caused more than 96 million infections and over 2 million deaths worldwide so far. However, there is no approved vaccine available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease causative agent. Vaccine is the most effective approach to eradicate a pathogen. The tests of safety and efficacy in animals are pivotal for developing a vaccine and before the vaccine is applied to human populations. Here we evaluated the safety, immunogenicity, and efficacy of an inactivated vaccine based on the whole viral particles in human ACE2 transgenic mouse and in non-human primates. Our data showed that the inactivated vaccine successfully induced SARS-CoV-2-specific neutralizing antibodies in mice and non-human primates, and subsequently provided partial (in low dose) or full (in high dose) protection of challenge in the tested animals. In addition, passive serum transferred from vaccine-immunized mice could also provide full protection from SARS-CoV-2 infection in mice. These results warranted positive outcomes in future clinical trials in humans. Supplementary Information The online version contains supplementary material available at 10.1007/s12250-021-00376-w.
Databáze: OpenAIRE
Externí odkaz: